John Parkinson

With these results, the company plans to submit their investigational vaccine, MRNA-1345, for regulatory approval in the first half of 2023.

This live-attenuated investigational vaccine was developed by Codagenix, which uses its codon de-optimization platform for its candidates.

A CDC report looked at 2 vaccine safety surveillance systems for the bivalent boosters in this population and there were no reports of myocarditis or death. Many of the reports were due to vaccine errors and not adverse events.

The two agencies said one of the vaccine surveillance systems prompted an investigation into whether there was a safety concern for ischemic stroke in seniors for this booster.

A randomized trial found the antidepressant to be ineffectual in helping improve time to sustained recovery.

A 2-year retrospective study looking at patients admitted to the ICU showed that the number of intubated males infected with Acinetobacter baumannii (AB) was double the number of intubated females.

Recent numbers show a lack of new people entering the field combined with existing shortfalls in many US locations.These factors demonstrate a potentially dangerous reduction in this vital medical specialty.

Clostridioides difficile (CDI) and recurrence can create a tremendous burden on patients’ quality of life as well as become a financial burden to individual healthcare systems thus creating downstream costs for individual hospitals.

The agency licensed the new indication for Sanofi’s Adacel (Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine, Adsorbed [Tdap]) shot for immunization during the third trimester of pregnancy.

Research will focus on new technologies for early diagnosis of severe illnesses resulting from SARS-CoV-2 infection.

The company is moving forward with vaccines to address respiratory and latent viruses as well as oncology.

The investigational antiviral showed the potential of another therapy that could benefit this patient population that is at risk for hospitalization and death.

Newer diagnostic technologies can play a role in identifying specific bacterium, decrease the time to optimal therapy, and offer the possibility of better outcomes.

Central Ohio has seen 82 pediatric cases since November, and more than a third of children infected have been hospitalized.

Developed by Sanofi and AstraZeneca, the single-dose long-acting antibody was designed to help protect all infants from birth through their first respiratory syncytial virus (RSV) season.

A new Infectious Diseases Society of America (IDSA) board member and vice president offers some insights on the leadership’s goals and direction for 2023.

The company’s vaccine candidate, MenABCWY, which is indicated for adolescents was given a Prescription Drug User Fee Act (PDUFA) goal date for later this year.

One clinician offers some insights on the RSV surge witnessed last year and the prospective benefits of having a maternal vaccine to protect newborns from this virus.

A look back on some of the significant discussions with clinicians, researchers, and infectious disease stakeholders.

The new recommendation from the organization believes it will help avoid delays in patient care.

Virax Biolabs has developed a T-cell testing platform to develop an immune risk profile against viral threats.

This therapy is the first of a new class of antiretrovirals, and it is indicated for people with multi-drug resistance, intolerance, or safety considerations.

Roche’s Actemra is the first FDA approved monoclonal antibody to be used for COVID-19.

The committee will meet on January 26 to discuss whether and how the composition for primary doses of the currently available COVID-19 vaccines should be modified.

In a new CDC report, these immunizations aid against emergency department and urgent care encounters in immunocompetent adults.

The New Drug Application (NDA) for the company’s investigational therapy, Olorofim, looks to serve an unmet medical need in this treatment space.

The Centers for Disease Control and Prevention (CDC) is looking into the possibility of this rare group of infections emerging.

A new CDC report highlights another health-related area where interruptions occurred due to the pandemic, but data suggests both improved rapidly.

TP-05, a novel, oral therapeutic recently reported topline results from its phase 1 study.

A large health system saw a reduction of 40% and 70% respectively when the antiviral was prescribed.